×
收藏-健康|会(x)员访问记?/h3>
| |页标题Q? | |
×
注册健康|用?/h3>
| ??名：(x) | ||
|---|---|---|
| ?p?人：(x) | ?nbsp; 别：(x) | |
| ?nbsp; 码：(x) | ||
| 重复密码Q?/th> | ||
| ?sh)子邮箱Q?/th> | ||
| 邮箱验证码：(x) | ||
| 固定?sh)话Q?/th> | ||
| ?nbsp; 真：(x) | ||
| ?nbsp; 机：(x) | ||
| 单位名称Q?/th> | ||
| 通信地址Q?/th> | ||
| 首选栏目：(x) | ||
| 我已l认真阅dƈ同意《健L(fng)服务条款?/a> | ||
| 定注册 | ||
UCB与诺华签|h(hun)D15亿美元合作协议，研发q商业化抗帕金森病药?/H1>
作者：(x)yuanxc 来源Q互联网 点击敎ͼ(x)0 更新旉Q?021-12-9 15:09:40
[关键字]Q?/font> UCB 诺华 帕金病 License in UCB0599 UCB7853
健康|讯Q?/FONT>
比利时制药公司UCB与瑞士制药公司诺华签|一h(hun)值高?5亿美元的合作协议Q共同研发和商业化其两个处开发阶D늚抗帕金森病药物——U(ku)CB0599和UCB7853?
×
健康|提C?/span>
相关q接
阿斯利康与Ionis达成合作 共同开发Eplontersenq将其商业化
Interpretation of The Notice on The Implementation Plan for Promoting The High-quality Development of The API Industry
琅钰集团与Rhythmq见遗传性肥胖疾病药物达成独家许可协?/a>
Saponin reference price
Chlorpheniramine Maleate reference price
Caffeine reference prices of main producers
Analgin reference prices of main producers
Aspirin reference prices of main producers
Interpretation of The Notice on The Implementation Plan for Promoting The High-quality Development of The API Industry
琅钰集团与Rhythmq见遗传性肥胖疾病药物达成独家许可协?/a>
Saponin reference price
Chlorpheniramine Maleate reference price
Caffeine reference prices of main producers
Analgin reference prices of main producers
Aspirin reference prices of main producers